(包括註冊人主要行政辦公室的地址，郵政編碼以及電話號碼(包括區號))

服務代理人姓名、地址（包括郵政編碼）及電話號碼（包括區號）

擬議中的公開發售開始日期： 在本登記聲明的生效日期之後不時

如果此表格上僅登記的證券是根據股息或利息再投資計劃提供的，請勾選下列方框：☐

如果該表格上登記的任何證券將根據1933年證券法規下規則415提供延遲或連續的基礎，除了僅與股息或利息再投資計劃相關提供的證券外，請勾選下列方框：☒

如果此表格是根據《證券法》規定第462（b）條規定的註冊額外證券的表格，請勾選下面的框，並列出該名早期有效註冊聲明的《證券法》註冊聲明編號，以供同一發行使用。☐

如果此表格是根據《證券法》規定第462（c）條而提交的後期有效修改的表格，請勾選下面的框，並列出同一發行的早期有效證券法註冊聲明的《證券法》註冊聲明編號。☐

如果此表格是根據I.D.常規指導原則（General Instruction I.D.）或其後期修正而提交的註冊聲明，在提交給證券交易委員會時應根據《證券法》第462（e）條生效，請勾選下面的框。☐

如果此表格是根據I.D.常規指導原則（General Instruction I.D.）提交的後期有效修改的註冊聲明，並根據《證券法》第413(b)條提交以註冊其他證券或其他類證券的，請勾選下面的框。☐

請在複覈標記內選擇是否爲大型快速備戰者，快速備戰者，非快速備戰者，較小的報告公司或新興生長公司。詳見交易所法案第120.2條中「大型快速備戰者」，「快速備戰者」、「較小的報告公司」和新興生長公司”的定義。

如果是新興成長公司，請勾選此項，以指示註冊人已選擇不使用根據證券法第7(a)(2)(B)條規定提供的任何新的或修訂的財務會計準則的延長過渡期以符合。☐

註冊管理人員在必要時會修改該註冊聲明的生效日期，直到註冊管理人員提交另一份明確說明該註冊聲明隨後將根據1933年證券法第8(a)條的規定生效的修正案爲止，或者，直到證券和交易委員會根據該條第8(a)條的規定確定該註冊聲明的日期爲止。

《基準招股說明書》緊隨本說明書而來。任何將根據基準招股說明書提供的證券的具體條款將在基準招股說明書的招股說明書補充中指明。銷售協議招股說明書補充緊隨《基準招股說明書》。根據銷售協議招股說明書補充可能發行、發行和出售的3556586美元普通股已包括在我們根據基準招股說明書發行、發行和出售的1億美元證券中。銷售協議終止後，《銷售協議招股說明書補充》中未根據銷售協議出售的3556586美元的任何部分將可供根據基準招股說明書的其他要約出售，如果在銷售協議下未出售任何股份，則完整的3556586美元證券可根據基準招股說明書的其他要約出售。

此初步招股說明書中的信息並不完整，可能會發生變化。在提交給證券交易委員會的註冊聲明生效之前，我們將無法賣出這些證券。此初步招股說明書並非要約出售這些證券，也沒有在任何不允許出售的司法管轄區域徵求購買這些證券的要約。

我們可以在一項或多項發行中從時間到時間出售上文所述證券的總額最高達1億美元。本招股說明書爲您提供了對證券的一般描述。

每次我們提供並賣出證券時，我們將提供一個或多個補充招股說明書，其中包含有關該發行的具體信息，包括證券的金額、價格和條款。補充招股說明書還可能添加、更新或更改相關發行的招股說明書中包含的信息。在投資我們的任何證券之前，您應仔細閱讀本招股說明書和所有適用的招股說明書補充，以及我們通過引用的文件。

我們可能會透過一個或多個承銷商、經銷商和代理商提供及賣出本招股說明書及任何附錄招股說明書所描述的證券，或直接銷售給購買者，或通過這些方法的組合。如果有任何承銷商、經銷商或代理商參與任何證券的銷售，則他們的名稱及他們之間或與之間的任何適用購買價格、費用、佣金或折扣安排將在相關附錄招股說明書中列明，或可由該等資訊推算出，至少在法律規定的情況下。有關更多資訊，請參閱本招股說明書標題為「」的部分。有關本招股章程”和“配售計劃未提供本招股說明書及描述這些證券發售方法和條款的任何適用附錄招股說明書，則不得出售任何證券。

我們的普通股在納斯達克全球貨幣市場以代號“CDt”交易。截至2024年10月16日，在納斯達克全球貨幣市場最後報告的普通股交易價格為0.114美元。

截至2024年10月16日，我們未受關係人持有的普通股的總市值約為10,669,758美元，根據該日期未受關係人持有的65,862,708股普通股，以及2024年8月26日我們普通股的最後報價0.162美元每股計算。根據S-3表格的一般指示I.b.6，我們不會在任何12個月期間賣出註冊在本招股說明書的登記聲明書上價值超過我們未受關係人持有的普通股總市值三分之一的證券，前提是我們未受關係人持有的普通股總市值不超過75,000,000美元。截至本招股說明書日期，我們未根據S-3表格的一般指示I.b.6，在招股說明書本部分所在的登記聲明書上提供任何證券，在招股說明書的日期之前的12個日歷月內及包括本招股說明書日期。

投資我們的證券存在風險。請查看本招股說明書第3頁。 “風險因素” 本招股說明書和適用招股補充說明書中的類似部分，以及參考資料中關於您在投資我們的證券之前應考慮的因素。 投資我們的證券之前，請查閱本招股說明書第3頁和任何相關部分，以及透過引用資料中提及的因素。

美國證券交易委員會或任何州證券委員會未核准或未核准這些證券，也未就本招股說明書的充分性或準確性作出判斷。對此顯得相反的陳述為刑事犯罪。

此招股說明書是我們與美國證券交易委員會（“SEC”）一起提交的S-3表格註冊聲明書的一部分，利用“架構”註冊流程。在這個架構註冊聲明書流程下，我們可以不時以總值高達1億美元的一次或多次發行任何這些有價證券的普通股、優先股、購買普通股或優先股的認股權證以及/或購買這些證券的任何單個或與本招股書中描述的其他證券結合的市場單位，本招股書向您提供了我們可能發行的證券的一般描述。

每當我們賣出本招股說明書中的任何類型或系列證券時，我們將提供一份招股說明書補充，其中將包含更具體的有關該發行的條款信息。我們還可能授權提供一份或多份自由書面招股說明書給您，可能包含與這些發行相關的重要信息。我們可能授權提供給您的招股說明書補充和任何相關的自由書面招股說明書，也可能補充、更新或更改本招股說明書或我們已納入本招股說明書的參考文件中包含的信息。本招股說明書及適用的招股說明書補充，任何相關的自由書面招股說明書，以及本招股說明書與適用的招股說明書補充中納入的參考文件，將包含有關適用發行的所有重要信息。在購買任何所提供證券之前，我們敦促您仔細閱讀本招股說明書、所有適用的招股說明書補充，以及我們授權用於特定發行的任何相關自由書面招股說明書，以及根據“」中描述的在此引用的其他信息。部分資訊文獻連結.”

除非添附有說明書補充資料，否則本說明書不得用於進行有價證券的銷售。

您應該只依賴本招股說明書中包含或參照的信息和適用的招股說明書補充資料，以及包含在我們已經授權在某一特定發行活動中使用的任何自由書面招股說明書中的信息。我們尚未授權任何人向您提供不同或額外的信息。沒有經銷商、銷售人員或其他人被授權提供任何不包含或未納入本招股說明書、任何適用的招股說明書補充資料或我們授權向您提供的任何相關自由書面招股說明書中的信息，也沒有人被授權代表任何東西。本招股說明書僅是出售此處所提供的證券的要約，但僅限於符合法律要求的情況和司法管轄區。

您應該假設此招股說明書、任何適用的招股說明書補充資料或任何相關的自由書面招股說明書中的信息僅截至文件正面日期時為準，我們參考的任何信息僅截至參考文件日期為止，而不論交付此招股說明書、任何適用的招股說明書補充資料或任何相關的自由書面招股說明書，或我們證券的銷售日期。自那日期以來，我們的業務、財務狀況、經營成果和前景可能已發生變化。

本招股說明書包含了部分描述在此提及的文件中的條文摘要，但完整信息應參酌實際文件。所有摘要均受到實際文件的完全資格約束。本招股說明書所提及或將提及的某些文件副本已經提交，將提交，或將被引用為本招股說明書所屬的登記聲明的附件，您可以按照“所以板塊”中描述的方式獲得這些文件的副本。在哪裡你可以找到額外資訊.”

以下摘要突顯了本招股章程其他地方所載信息或參照的內容，並且並不包含可能對我們證券的購買者很重要的所有信息。在購買所提供的任何證券之前，您應該仔細閱讀本章程、所有參照的文件、任何招股補充說明書和任何相關的自由書面招股章程，以及本章程“”部分描述的其他信息。在哪裡你可以找到額外資訊在購買所提供的任何證券之前，請仔細閱讀本章程、所有參照的文件、任何招股補充說明書和任何相關的自由書面招股章程，以及本章程所述的其他信息。除非明示指出或情況另有要求，在本章程中對“公司”、“申報人”、 “我們”、“我們”及“我們”的引用均指Conduit Pharmaceuticals Inc.及其子公司在合併基礎上（並且將Old Conduit的業務（在實施下文所定義的業務組合之後成為公司業務）的業務納入其中），除非上下文另有要求。

此摘要突出了本招股說明書中其他地方包含的選定信息，或者是透過參考而納入本招股說明書中的信息，但並不包含您在作出投資決定時需要考慮的所有信息。您應該仔細閱讀整個招股說明書、所有適用的招股說明書補充資料，以及任何相關的自由書面招股說明書，包括討論我們證券投資風險的部分。 “風險因素” 包含在本招股說明書中、所有適用的招股說明書補充資料，以及任何相關的自由書面招股說明書內的信息，以及在被納入本招股說明書的其他文件中相關標題下的信息。您還應仔細閱讀被納入本招股說明書中的參考信息，包括我們的基本報表和構成本招股說明書一部分的登記聲明書所附的展示資料。

Conduit已經開發出一種獨特的業務模式，使其能夠充當一個管道，從藥品公司引入臨床資產並開發新的治療方案給患者。我們的新穎方法解決了未被滿足的醫療需求，通過尖端的固形技術延長了我們現有資產的知識產權，然後將這些產品與生命科學公司商品化。

同時利用我們劍橋實驗室設施和經驗豐富的固相專家團隊的能力，擴展或開發我們現有和未來臨床資產的專有固相智慧財產。我們自有的智慧財產組合包括在幾個國際司法管轄區內的未決專利申請，描述一種固相化合物，AZD1656共晶體（一種Hk-4葡萄糖激酶激活劑），瞄準多種自體免疫疾病。我們的管線研究包括許多化合物，可作為現有大型藥品公司目前推出並銷售的臨床資產的有希望的替代品，我們已確認具有機會透過固相技術進一步開發智慧財產位。

在資金和臨床資產的開發方面，我們評估和選擇要開發的具體分子，並與外部醫藥外包概念（"CROs"）和關鍵意見領袖（"KOLs"）合作進行由我們管理、資助和監督的臨床試驗。我們打算利用我們全面的臨床和科學專業知識，通過使用醫藥外包概念和第三方服務提供商，以高效的方式進行第II期臨床試驗，促進臨床資產的開發。我們還將與特定疾病的KOL密切合作，共同評估並判斷所有我們現有和即將來臨的資產最適合的適應症。

我們相信，在我們的產品系列中成功進行第二期臨床試驗將會增加我們資產的價值。然而，我們無法保證我們所擁有或許可的資產進行的任何臨床試驗都會成功，但在成功進行第二期臨床試驗後，我們將尋求與大型生物科技公司或藥品公司的許可機會，通常為了前期里程碑付款和資產專利期間的權利金收入。我們預期將利用未來的權利金收入來開發我們的資產組合，並與其他潛在的融資來源結合，包括債務或股權融資。

除我們擁有的專利臨床資產外，阿斯利康同意根據阿斯利康所控制的與Hk-4葡萄糖激酶激活劑AZD1656和AZD5658以及粒線體過氧化物酶抑製劑AZD5904相關的智慧財產權，授予公司許可證。該許可證涵蓋所有症狀領域以及男性不孕的治療、預防和預防性用途。公司將負責根據相關的授權協議（“授權產品”）開發和商業化相關產品。公司必須盡商業上的合理努力開發和商業化授權產品。

我們計劃專注於開發臨床資產，以解決影響大眾的疾病，在目前沒有治療方法或是現有治療方法會帶來顯著的不良副作用。

我們打算啟動第2a期臨床試驗，評估AZD1656對系統性紅斑狼瘡（包括狼瘡腎炎）和ANCA相關血管炎的治療作用。這代表了AZD1656的重要發展，凸顯了我們對解決未滿足的醫療需求的承諾，以及對該資產潛在影響患者結果的信懇智能。

進行第2a階段雙盲安慰劑對照試驗，涉及系統性紅斑狼瘡和狼瘡腎炎患者以及患ANCA相關血管炎的患者，將讓我們評估AZD1656在整個狼瘡患者領域的潛力。同時，我們將評估AZD1656在自體免疫性疾病更廣泛範疇的潛力。

2023年9月22日，Conduit Pharmaceuticals Limited（"OldConduit"）和Murphy Canyon Acquisition Corp（"MURF"）以及MURF的全資子公司（"Merger Sub"）之間的合併交易（"業務合併"）已根據已修訂的《合併協議》（即2022年11月8日簽署）完成。根據合併協議條款，在交易完成時，（i）Merger Sub與OldConduit合併，OldConduit作為MURF的全資子公司在業務合併中存活，（ii）MURF將其名稱從Murphy Canyon Acquisition Corp 更改為Conduit Pharmaceuticals Inc。

我們的主要行政辦公室位於加州聖地牙哥市萬華峽道4995號300室，電話號碼為(760) 471-8536。我們的網站地址是 http://www.conduitpharma.com。我們網站上包含的或通過其他方式可訪問的資訊不包含於本招股說明書中。

投資在我們的證券中涉及高程度的風險。在做出投資本公司證券的決定之前，您應仔細小心考慮下面描述的特定風險因素並在標題的部分中討論 「風險因素」 包含在截至二零二三年十二月三十一日止財政年度有關表格 10-k 年度報告，以下標題 “項目 1A。風險因素，” 以及以下標題下的表格 10-Q 的任何後續季度報告中所述或可能描述 “項目 1A。風險因素，” 以及所有適用的招股章程補充文件中，並包含或將包含在我們向美國證券交易委員會提交的文件中並以參考方式納入本招股章程，以及本招股章程中所包含的所有其他資料，或任何適用的資料招股章程附件。如需這些報表和文件的描述，以及您可以在哪裡找到它們的資訊，請參閱「在哪裡您可以找到其他信息」和「通過參考合併某些信息.” 如果有我們的 SEC 文件或任何招股章程補充文件中描述的風險或不確定性，或實際上任何其他風險和不確定性如果發生，我們的業務、財務狀況和營運結果可能會受到重大和不利影響。在這種情況下，交易我們的證券價格可能下跌，您可能會損失所有或部分投資價值。

我們目前的營運資金有限，並且持續承擔營運成本和費用。我們目前的支出和繼續進行的營運需要有相當額外的資本，這些資本可能無法以可接受的條件向我們提供，甚至無法提供，如果無法提供這些資本，可能需要我們延遲、限制、減少或停止我們的營運，甚至通過破產或清算進行。

自我們創立以來，我們的業務已經消耗了大量現金。截至2024年6月30日，我們積累的虧損為$20.2百萬美元，截至2024年6月30日結束的季度淨虧損為$540萬。截至2024年10月16日，我們擁有約$6.5萬的現金及現金等價物。我們預期將繼續承擔重大費用和不斷增加的營運虧損。我們的業務需要額外的資本來維持營運。全球經濟條件可能惡化，並可能受美國信貸和金融市場的最近干擾和波動影響，進而對我們籌集額外資金的能力產生不利影響。由於我們需要額外資金，我們可能會透過出售額外的股權證券、債務融資和/或戰略合作協議來支持我們的業務運作。我們無法確定從這些來源獲得額外融資是否會在需要時提供，或者即使提供，額外融資是否會以有利條件獲得。

如果我們在短期內無法籌集到額外的資本，可能會被要求大幅減少、縮減或停止我們的業務，甚至通過破產或清算方式。我們可能被迫出售或處置我們的權益或資產。任何無法以商業上合理條件籌集足夠資金的情況都可能對我們的業務、運營結果和財務狀況產生重大不利影響，包括資金不足可能導致我們的業務失敗，公司申請破產或解散清算，而投資者幾乎無法獲得回報。

我們的業務取決於我們的臨床資產的成功開發、監管批准和商業化，特別是我們相信可以用於一系列自身免疫性疾病的葡萄糖激酶激活劑，我們將其稱爲AZD1656和AZD5658，以及一種強效的、不可逆的人類過氧化物酶抑制劑，有潛力治療特發性男不育症，我們將其稱爲AZD5904。

我們業務的成功，包括我們資金運作能力和未來營業收入的產生，主要取決於我們臨床資產的成功開發、監管批准、商業化或合作伙伴關係的建立。未來，我們可能也會依賴於我們的某一個臨床資產或者我們可能在許可、收購或開發的任何未來臨床資產。我們臨床資產的臨床前、臨床和商業成功將取決於許多因素，包括以下內容：

如果我們無法及時或根本無法實現上述的一個或多個因素中的許多因素，其中許多因素超出我們的控制範圍，我們可能會遇到重大延遲和成本增加，或者無法獲得監管批准或使我們的臨床資產商業化。即使獲得監管批准，我們也可能永遠無法成功地將任何一項臨床資產商業化。因此，我們無法保證投資者我們能夠通過銷售我們的臨床資產或任何未來的臨床資產產生足夠的營業收入以繼續運營。

我們的臨床資產（AZD1656、AZD5658和AZD5904）的開發費用高昂、耗時長且不確定。無論是臨床前還是臨床試驗可能都無法充分展示感興趣的治療領域內的藥理活性；可能會在其他身體系統中引起意想不到的短期或長期影響；或產生意外的毒性，可能改變或增加風險評估。此外，即使早期研究顯示潛力，後續臨床試驗可能無法複製結果，導致延遲、成本增加或監管批准失敗。

構成我們努力生成和開發臨床資產基礎的科學發現相對較新，給這一過程增加了進一步的複雜性和風險。AZD1656是一種葡萄糖激酶活化劑，可能在多種II期就緒的自身免疫性疾病中表現出療效，包括狼瘡性腎炎、ANCA相關血管炎、葡萄膜炎、Hashimoto氏甲狀腺炎、早產和腎移植失敗。然而，要成功開發可能需要進一步的研究和努力來優化其治療潛力。AZD5685是一種Hk-4葡萄糖激酶活化劑，具有與AZD1656相同的作用機制，並且在各種自身免疫性疾病中已經具備II期就緒。此外，我們的開發管線包括我們認爲是對人類髓過氧化物酶（MPO）的有效不可逆抑制劑，有潛力治療特發性男性不育症，我們稱之爲AZD5904。AZD5904在患者身上可能無法展示實驗室或臨床前研究中賦予其的治療特性，並且可能與人類生物系統發生意想不到、無效甚至有害的相互作用。如果我們無法成功開發和商業化我們的臨床資產，包括AZD1656、AZD5658和AZD5904，我們可能永遠無法盈利，而我們的資本股價的價值可能會下降。

我們已經確定了我們財務報告內部控制存在重大缺陷。如果我們不能糾正這些缺陷或者維持一個有效的內部控制系統，那麼我們生產準確及及時的財務報表或者遵守適用規定的能力可能會受到不利影響。我們可能會發現我們財務報告內部控制額外重大缺陷這些缺陷可能無法及時糾正。

在準備和審計截至2023年12月31日和2022年財政年度的基本報表的過程中，我們發現了我方財務報告的內部控制存在重大缺陷。重大缺陷是指在財務報告的內部控制中存在缺陷，或缺陷的組合，使得年度或中期財務報表可能無法及時防止或檢測到重大錯誤。這些重大缺陷主要與以下與我們財務報表編制相關的事項有關：

如果這些實質性弱點未得到糾正，可能導致帳戶餘額或披露的錯誤陳述，進而導致年度或中期基本報表出現實質性錯誤陳述，這些錯誤將無法被預防或檢測。我們正在實施旨在改善我們的財務報告內部控制以糾正這些實質性弱點的措施，儘管截至招股說明書日期，這些實質性弱點尚未完全得到糾正。

直到我們的整改計劃完全實施，適用的控制措施運行一段足夠的時間，並且我們通過測試得出結論，新實施和加強的控制措施有效運行後，這些重大缺陷才不會被視爲得到整改。我們目前沒有財務資源來建立和實施整改計劃。公司期望一旦擁有了這樣的財務資源，便能開始執行整改計劃，通過記錄和實施該計劃，並隨後對這些控制措施進行測試。我們無法預測這些努力的成功與否或對任何這樣的整改努力評估的結果。一旦開始，我們的努力可能無法整改我們財務報告內部控制中的這些重大缺陷，或者未來可能會發現其他重大缺陷。未能實施和保持有效的財務報告內部控制可能導致財務報表中的錯誤，從而導致財務報表重新編制，並可能導致我們未能滿足報告義務，其中任何一個均可能減弱投資者對我們的信心並導致我們的普通股價格下跌。

我　們　獨　立　的　註冊　會　計　師　公　司　不需　要　正　式　認　定　我　們　的　內　部　控　制　效　能　的　有　效　性　，直　至　我　們　不　再　是　「新　興　生　長　公　司　」，如　在　JOBS　法　案　中　定　義　。在　那　時　，我　們　獨　立　的　註冊　會　計　師　公　司　可　能　就　我　們　的　內　部　控　制　效　能　的　記錄　、設　計　或　運　作　水　平　不　滿　意　發　表　負　面　報　告　。

目前，我們依賴與第三方達成協議來許可我們的臨床資產。在短期內，我們打算繼續依賴第三方許可臨床資產，以及未來合作可能產生的資產。

我們目前依賴與第三方的協議來許可大型藥品公司的臨床資產。例如，我們與阿斯利康簽訂了許可協議，根據該協議，我們直接從阿斯利康許可臨床資產。如果我們違反協議，這種協議的終止可能會嚴重影響我們的業務、財務狀況、運營結果和前景。我們的業務策略在很大程度上依賴於我們商業化臨床資產的能力，而且我們進入並維持與這些臨床資產相關的許可協議對我們的運營成功至關重要。此外，雖然我們持有與阿斯利康協議範圍之外的自有知識產權，但協議的終止可能會對我們的業務和商業化臨床資產的能力產生不利影響。

我們股權證券的集中持有可能會延遲或阻止控制權的轉變。

截至2024年10月16日，科爾維斯資本有限公司（其中董事葛根是首席執行官），量化控股公司和葛根個人共同持有我們普通股30,292,731股，約佔我們流通在外的普通股的31.55%，阿斯利康持有我們普通股9,504,465股，約佔我們流通在外的普通股的9.9%。因此，我們少數股權持有者可能有能力決定公司需要股東批准的公司行動的結果，包括選舉董事會的所有董事和批准重大公司事項。這種所有權集中可能會導致延遲或阻止控制權變更，並可能對我們的普通股市場價格產生不利影響。

由於與一家特殊目的收購公司的業務合併，監管義務可能會對我們產生不同於其他上市公司的影響。

通過與MURF完成的商業組合，我們成爲一家已公開交易的公司，MURF是一家特殊目的收購公司（" SPAC"）。由於商業組合以及其中涉及的交易，我們的監管義務可能會影響我們與其他已公開交易公司的情況有所不同。例如，SEC和其他監管機構可能會向像我們這樣已與SPAC完成業務組合的公司發佈額外指導，或者對其進行進一步的監管審查。管理這種監管環境，可能會需要不斷髮展，可能會轉移管理層的注意力，從而影響我們業務的運作，對我們提高資本的能力造成負面影響，或對我們的普通股價格產生不利影響。

我們的普通股票在納斯達克全球市場上市，我們的可贖回權證也在納斯達克全球市場上市。儘管我們已達到納斯達克的最低初始上市標準，這通常只需要我們滿足與股東權益、市值、公開持股的市場總值和分銷要求相關的某些要求，但我們無法保證我們的證券將來會繼續在納斯達克上市。

例如，我們最近收到了納斯達克發出的多個上市違規通知，如本招股說明書所披露的，涉及我們審計委員會的組成，以及我們未能滿足納斯達克有關最低買盤價格、公開持股市值和上市證券市值的持續上市要求。儘管我們打算在（i）審計委員會組成至少由三名獨立董事組成的要求規定的解疑期滿之前恢復合規，（ii）買盤價格規則，其中可能包括實施股票拆分，（iii）MVPHS要求和（iv）MVLS要求，但無法滿足納斯達克的持續要求或標準可能導致我們的普通股除牌，這可能會對我們的財務狀況產生重大不利影響，並使普通股價值下降。

如果我們的普通股票從納斯達克全球市場上除牌，並且股票市場價格低於$5.00每股在普通股被除牌的日期當天，我們的普通股票交易也將受到《交易所法》規定的某些規則的約束。這些規則要求經紀商在涉及「一分錢股票」的任何交易時進行額外披露，並對向非建立客戶和合格投資者（通常是機構）出售一分錢股票的經紀商施加各種銷售規範要求。這些額外要求可能會阻止經紀商進行被分類爲一分錢股票的證券交易，這可能會嚴重限制這些證券的市場價格和流動性，以及購買者在二級市場中出售這些證券的能力。一分錢股票通常被定義爲任何市場價低於$5.00每股的非交易所上市的股權證券，受到某些例外的影響。

根據招股說明書發行的股票的銷售或可供銷售可能會壓低我們普通股的價格，稀釋現有股東的權益，並鼓勵第三者進行賣空榜，進一步可能壓低我們普通股的價格。

在投資者根據招股書補充拍賣我們普通股的情況下，我們普通股的市場價格可能會因市場上的額外賣壓而下跌。由於這些股票的出售或潛在出售可能導致我們普通股價格下跌，進而鼓勵第三方進行賣空榜交易。這種交易可能通過增加我們普通股的出售數量，從而對我們普通股的市場價格施加下行壓力，進一步有助於推動我們普通股的市場價格下跌。

Corvus資本有限公司是我們的重要股東之一，也是我們一位董事控制的實體，在與Nirland達成的協議中，抵押了其所持有的所有普通股，如果根據該協議這些已抵押的股份轉移給Nirland，Nirland將對我們產生重大影響。

所有板塊我們普通股的所有股份，約3000萬股（佔我們流通普通股的31%）已質押給Nirland，與兩方先前達成的參與和誘因協議有關。根據該協議，Corvus Capital Limited及其關聯公司與Nirland簽訂了一項參與和誘因協議，Corvus Capital Limited同意在其有益所有的普通股出售或質押的情況下向Nirland提供某些支付和經濟利益。根據該協議，在某些情況下，Nirland可能有權要求Corvus Capital Limited向其轉讓部分這些股份。如果轉讓所有或其中部分這些股份，Nirland可能擁有大量我們的流通普通股。這種所有權的集中可能對我們產生不利影響，包括但不限於延遲或阻止控制權的變更，影響提交給我們股東審批的公司行動投票結果，可能對我們的普通股市場價格產生不利影響。

債務協議爲Nirland提供對我們所有資產的留置權，包括我們的知識產權，幷包含財務契約和其他對我們行動的限制條件，這可能給我們的股東帶來重大風險，並可能影響我們進行某些交易和經營業務的能力。

根據債務協議的條款，我們已經將幾乎所有資產，包括知識產權，作爲抵押物設定了留置權，並同意了重大契約，包括實質限制我們採取某些行動的契約，包括支付分紅派息的能力，進行某些投資和其他支付，負擔額外的債務，負債並處置資產以及，包括未能支付到期金額，違反契約和擔保，重大不利影響事項，某些交叉違約和裁決以及破產等常見的違約事件。

未能遵守這些協議的條款和其他規定，包括任何未能按時支付款項的情況，通常會導致這些工具下的違約事件。如果我們無法按時償還到期的債務，有擔保的貸款人可能會對擔保該債務的資產進行贖回和出售，其中包括幾乎所有我們的資產，以滿足我們的支付義務，這可能會阻止我們訪問這些資產以進行業務並按照計劃進行業務。由於這些事件的任何一種可能會對我們的業務、財務狀況、前景和運營結果造成重大不利影響。

我們將來可能需要大量額外的資金，這些資金可能無法以可接受的條件或根本無法獲得，如果沒有這些資金，可能會迫使我們延遲、限制、減少或停止我們的業務。

自創立以來，我們的業務運營消耗了大量現金。截至2024年6月30日，我們累積虧損2002萬美元，並於2024年6月30日結束的六個月內虧損290萬美元。我們預計在可預見的未來將繼續承擔重大費用和逐漸增加的營運虧損。我們的業務將需要大量額外資金來實施我們的長期業務計劃和發展臨床資產。可能受全球經濟狀況潛在惡化以及美國信貸和金融市場最近的干擾和波動影響，我們籌集額外資金的能力可能受到不利影響。在需要額外資金時，我們可能通過出售額外的股權證券、債務融資和/或戰略合作協議來資助我們的業務運營。我們無法確定來自以上任何來源的額外融資在需要時是否可獲得，或者即使可獲得，是否能獲得優惠條件。

如果我們通過出售普通股或其他與股權掛鉤的證券籌集額外資金，我們現有股東的所有權利將被攤薄。我們可能會在條件有利時尋求進入公開或私人資本市場，即使此時我們並沒有迫切需要額外資本。如果我們通過與第三方合作、戰略聯盟、市場營銷、分銷或許可安排籌集額外資金，我們可能必須放棄對我們的技術、未來營業收入、臨床資產的寶貴權利，或以我們無法接受的條件授予許可。如果我們通過債務融資籌集額外資金，我們可能不得不將我們的資產擔保給未來的出借人，我們的債務服務成本可能相當高昂，並且任何現有或未來的債權人在涉及公司的任何未來破產或清算時可能處於優先地位。

2024年10月16日，我們公司的普通股最後報價爲在納斯達克報告的每股0.114美元。目前，公司認股權證的行權價格高於我們普通股的當前市場價格。因此，這些認股權證不太可能被行使，因此公司預計短期內不會從這些認股權證的行使中獲得任何收益。Warrants持有人是否決定行使這些認股權證，從而爲公司帶來現金收益，可能取決於任何持有人做出判斷時我們普通股的市場價格。

如果在需要時無法籌集額外資本，我們可能需要削減開發科技或大幅削減或減少業務。我們可能被迫出售或處置我們的權利或資產。在商業上合理條款下無法籌集足夠資金可能會對我們的業務、運營結果和財務狀況產生重大不利影響，包括資金不足可能導致業務失敗，公司解散並以較少甚至沒有回報給投資者。

根據本招股說明書，我們可以在不同時段以市場條件決定的價格和條款，爲了我們的普通股、優先股、購買普通股或優先股的認股證或單位以及/或其他證券，無論是單獨發行還是與本招股說明書中描述的其他證券組合發行，進行一次或多次發行。本招股說明書爲您提供了我們可能發行的證券的一般描述。每次我們發行某種類型或系列的證券，我們都會提供一份招股說明書，其中將描述證券的具體數量、價格和其他重要條款，包括如適用的：

我們授權提供給您的招股說明書補充以及任何相關的自由書面說明，可能會補充、更新或更改本招股說明書或我們已納入參考的文件中的信息。

本招股說明書可能不得用於提供或銷售證券，除非有招股說明書補充。

我們可能會直接或通過代理人、承銷商或經銷商出售證券。我們及我們的代理人、承銷商或經銷商保留接受或拒絕證券任何部分或全部的購買意向的權利。如果我們通過代理人或承銷商發行證券，我們將在適用的招股書補充中包括：

本招股說明書及我們在美國證券交易委員會提交的文件中包含的並被引用的內容涉及《1933年證券法》第27A條和《證券交易法》第21E條的「前瞻性聲明」。這些聲明涉及未來事件，或者我們未來的運營或財務表現，涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致我們的實際結果、表現或成就與前瞻性聲明中暗示的任何未來結果、表現或成就有實質區別。前瞻性聲明可能包括但不限於以下表述：

In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “intends,” “may,” “plans,” “potential,” “will,” “would,” or the negative of these terms or other similar expressions. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks in the section titled “Risk Factors”, in any prospectus supplement and free writing prospectuses we may authorize for use in connection with this offering, and in our most recent Annual Report on Form 10-K, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should read this prospectus, together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements.

We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement.

The following is a description of our securities of as set forth in certain provisions of our Second Amended and Restated Certificate of Incorporation (the “Charter”) and our Amended and Restated Bylaws (the “Bylaws”), each previously filed with the SEC and incorporated by reference as an exhibit to this registration statement. This summary does not purport to be complete and is qualified in its entirety by the full text of the Charter, Bylaws, and the applicable provisions of the Delaware General Corporation Law (the “DGCL”). We encourage you to read our Charter, Bylaws, and the applicable portions of the DGCL carefully, along with the terms of any securities offered for sale pursuant to a prospectus supplement.

The total amount of authorized capital stock of the Company consists of 250,000,000 shares of common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”).

As of October 16, 2024, our issued and outstanding capital stock consists of 100,774,035 shares of common stock and no shares of Preferred Stock.

The holders of the common stock are entitled to one vote for each share held of record on all matters to be voted on by stockholders. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the voting power represented by shares of common stock voted for the election of directors can elect all of the directors.

Subject to applicable law and the rights, if any, of the holders of any outstanding series of the Preferred Stock, the holders of shares of common stock are entitled to receive such dividends and other distributions (payable in cash, property or capital stock of the Company) when, as and if declared thereon by the board of directors from time to time out of any assets or funds of the Company legally available therefor and shall share equally on a per share basis in such dividends and distributions.

Holders of common stock do not have any conversion, preemptive or other subscription rights and there is no sinking fund or redemption provisions applicable to the common stock.

Our common stock is listed on The Nasdaq Global Market under the symbol “CDT.”

The transfer agent and registrar for the common stock is Vstock Transfer, LLC, with an address of 18 Lafayette Place, Woodmere, NY 11598.

The following summary of certain provisions of our Preferred Stock does not purport to be complete. You should refer to the section of this prospectus titled “Anti-Takeover Effects of The Charter And The Bylaws” and to our Charter, our Bylaws, and the applicable provisions of the DGCL. This information is qualified entirely by reference to the applicable provisions of our Charter, Bylaws, and the DGCL. The rights, preferences, privileges and restrictions of the Preferred Stock of each series will be fixed by the certificate of designation relating to that series.

Our Charter authorizes the issuance of 1,000,000 shares of Preferred Stock by the board of directors, in one or more series, and the board of directors may establish the number of shares to be included in each such series and may fix the voting rights, if any, designations, powers, preferences and relative, participating, optional, special and other rights, if any, of each such series and any qualifications, limitations, and restrictions thereof.

The rights of Preferred Stock could adversely affect the voting power or other rights of the holders of common stock. In addition, the Preferred Stock could be utilized as a method of discouraging, delaying, or preventing a change in control of the Company.

As of the date of this prospectus, there were no shares of our Preferred Stock outstanding.

Our board of directors may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common stock. The issuance of Preferred Stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring, or preventing a change in control of our Company, which might harm the market price of our common stock. See also “Anti-Takeover Effects of The Charter And The Bylaws.”

Each series of Preferred Stock, if issued, will be more fully described in the particular prospectus supplement that will accompany this prospectus. To the extent required, this description will include:

The transfer agent and registrar for any series of Preferred Stock that is designated by our board of directors will be set forth in the applicable prospectus supplement.

The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and provisions of the warrants that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future warrants we may offer, we will describe the particular terms of any warrants that we may offer in more detail in the applicable prospectus supplement. The terms of any warrants we offer under a prospectus supplement may differ from the terms we describe below.

We may issue warrants for the purchase of common stock or Preferred Stock, in one or more series. We may issue warrants independently or together with common stock or Preferred Stock, and the warrants may be attached to or separate from our common stock or Preferred Stock.

We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants.

As of October 16, 2024, we have warrants outstanding to purchase an aggregate of 17,740,725 shares of common stock. If the number of outstanding shares of common stock is increased by a stock dividend payable in shares of common stock, or by a split-up of shares of common stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of common stock issuable on exercise of each whole Warrant will be increased in proportion to such increase in the outstanding shares of common stock. The warrant holders, solely by virtue of holding warrants, do not have the rights or privileges of holders of common stock or any voting rights until they exercise their warrants and receive shares of common stock.

We will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including:

Before exercising their warrants, holders of warrants will not have any of the rights of holders of common stock or Preferred Stock purchasable upon such exercise, including the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights:

Each warrant will entitle the holder to purchase the number of shares of common stock or Preferred Stock that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.

Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent.

Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the shares purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.

Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the State of Delaware.

每一家認股權代理將僅作爲我們在適用的認股權協議下的代理，不會承擔與任何認股權持有人具有代理或信託關係的任何義務或關係。一家銀行或信託公司可以作爲多個認股權發行的認股權代理。在我們違約的情況下，包括適用的認股權協議或認股權，任何認股權代理將不承擔任何職責或責任，包括任何啓動法律程序或採取其他行動的職責或責任，也不需要向我們提出任何要求。任何認股權持有人均可在不經相關認股權代理或任何其他認股權持有人同意的情況下，通過適當的法律行動來執行其行權權利，並收到行權後可以購買的證券。

下面的描述以及我們在任何適用的招股說明書補充中包含的額外信息總結了我們可能根據本招股說明書發行的單位的主要條款和規定。雖然我們以下面總結的條款通常適用於我們可能發行的任何未來單位，但我們將在適用的招股說明書中更詳細地描述我們可能發行的任何單位的特定條款。我們根據招股說明書補充提供的任何單位的條款可能與我們以下描述的條款有所不同。

我們可能發行由本招股說明書中描述的其他類別證券組成的單位，可以任意組合。每個單位都將按照使持有單位的人同時也是單位中包含的每種證券的持有人的方式發行。因此，單位的持有人將享有和負有每種包含的證券持有人的權利和義務。這些單位可能根據招股說明書中有關提供的單位而發行，該招股說明書將描述通過我們與單位代理之間簽訂的單位協議發行。招股說明書將描述：

本招股說明書及任何招股說明書補充中的單位描述，均爲適用單位協議的主要條款摘要。這些描述並未完全重述那些單位協議，並且可能不包含您可能發現有用的所有信息。我們建議您閱讀適用的單位協議，因爲它們而不是摘要，定義了您作爲單位持有人的權利。有關更多信息，請查閱相關單位協議的形式，這些形式將在發行單位之後及時提交給SEC，並按照所述在題爲“"的部分提供。您可以找到其他信息的地方.”

根據我們的章程規定，除非受限於任何未償還的優先股系列持有人的權利並受到適用法律的要求，股東特別會議，無論任何目的，只能由（i）董事會主席，（ii）首席執行官，或（iii）董事會多數票決召開。

根據我們的章程規定，在股東提名之前，股東必須以適當的書面形式適時向秘書提交提名申請。爲了及時，股東向秘書提交的通知必須在我們的首席執行辦公室收到（i）在年度股東大會的情況下，不得晚於前一次年度股東大會週年日期前90天的營業結束之前，也不得早於前一次股東年度大會週年日期前120天的營業結束之前；但是，如果年度股東大會早於或晚於該週年日期超過30天，通知股東以便及時接收不得早於該會議的120天營業結束之前，並且不得晚於（x）會議之前90天的營業結束，或者（y）公司首次公佈年度會議日期的第10天的營業結束之後；（ii）在公司公告目的是選舉董事的股東特別大會的情況下，不得晚於公司首次公佈特別會議日期後的第10天的營業結束。

我們普通股的過戶代理和註冊機構是VStock Transfer, LLC，地址位於Woodmere, New York 11598，電話：(212) 828-8436。

我們的已獲授權但尚未發行的普通股和優先股可用於將來發行，無需股東批准，可用於各種公司用途，包括未來的發行以籌集額外資本、收購和員工福利計劃。已獲授權但尚未發行和未預留的普通股和優先股的存在可能使通過代理大會、要約收購、合併或其他方式獲取公司控制權的嘗試變得更加困難或令人望而卻步。

Our Charter requires that, to the fullest extent permitted by the applicable law, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (iii) any action asserting a claim against the Company, its directors, officers or employees arising pursuant to any provision of the DGCL or the second amended and restated certificate of incorporation or the bylaws, or (iv) any action asserting a claim against the Company, its directors, officers or employees governed by the internal affairs doctrine and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder’s counsel except any action (A) as to which the Court of Chancery in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or (C) for which the Court of Chancery does not have subject matter jurisdiction. Notwithstanding the foregoing, (i) the foregoing will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction and (ii) to the fullest extent permitted by the applicable law, the federal district courts of the United States of America for the District of Delaware and the Court of Chancery of the State of Delaware shall have concurrent jurisdiction for the resolution of any complaint asserting a cause of action arising under the Securities Act or the rules and regulations promulgated thereunder.

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or any of the Company’s directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims. The Company cannot be certain that a court will decide that this provision is either applicable or enforceable, and if a court were to find the choice of forum provision contained in the Charter to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions, which could harm the Company’s business, operating results, and financial condition.

Our Charter provides that directors and officers will be indemnified by the Company to the fullest extent authorized by Delaware law as it now exists or may in the future be amended.

Our Bylaws also permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit indemnification. We have purchased a policy of directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances and insures the Company against its obligations to indemnify the directors and officers.

These provisions may discourage stockholders from bringing a lawsuit against the Company’s directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit the Company and the Company’s stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent the Company pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced directors and officers.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the Company’s directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, the Company has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depository or warrant agent maintain for this purpose as the “holders” of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as “indirect holders” of those securities.

As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.

We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary’s book-entry system. These participating institutions, which are referred to as participants, in turn hold beneficial interests in the securities on behalf of themselves or their customers.

Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.

As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker, or other financial institution that participates in the depositary’s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders, of the securities.

We may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in “street name.” Securities held by an investor in street name would be registered in the name of a bank, broker, or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account the investor maintains at that institution.

For securities held in street name, we will recognize only the intermediary banks, brokers, and other financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities.

Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.

For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so.

If you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check with your own institution to find out:

A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.

Each security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, the Depository Trust Company, or DTC, will be the depositary for all securities issued in book-entry form.

A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under “Special Situations When a Global Security Will Be Terminated.” As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security.

If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.

As an indirect holder, an investor’s rights relating to a global security will be governed by the account rules of the investor’s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.

If securities are issued only in the form of a global security, an investor should be aware of the following:

In a few special situations described below, the global security will terminate, and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above.

The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.

We may sell our securities covered by this prospectus in any of three ways (or in any combination):

Each time we offer and sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms of the offering, including:

經銷商允許或重新允許或支付的任何公開發行價格及折扣或讓利可能會不時更改。我們可以通過電子拍賣方式確定本招股說明書下提供的證券價格或其他條款。我們將描述拍賣如何確定價格或任何其他條款，潛在投資者如何參與拍賣以及承銷商、經銷商或代理人在適用招股說明書補充中的義務性質。

承銷商或經銷商可能不時以一種或多種交易方式出售所提供的證券，包括協商的交易，以固定的公開發行價格或在銷售時確定的不同價格。如果承銷商或經銷商用於銷售任何證券，這些證券將由承銷商或經銷商自行購買，並可能不時以上述一種或多種交易方式再次出售。這些證券可以通過由主承銷商代表的承銷團體向公衆提供，或直接由承銷商或經銷商提供。通常，承銷商或經銷商的義務購買這些證券將受到某些前提條件的約束。如果承銷商或經銷商購買任何證券，則他們將有責任購買所有證券，除非在招股書附錄中另有規定。我們可能使用我們存在重大關係的承銷商。我們將在招股書附錄中描述任何此類關係的性質，並命名該承銷商。

我們可能會不時通過代理銷售證券。招股說明書將列出參與證券發行或銷售的任何代理商以及我們支付給他們的任何佣金。一般來說，任何代理商在其任職期間將以盡最大努力行事。我們可能授權承銷商、經銷商或代理商根據招股說明書中所載的公開發行價，通過延遲交割合同爲一些購買者徵詢購買證券的要約，合同規定在將來某個指定日期支付和交割。合同僅受限於招股說明書中規定的條件，而招股說明書將規定我們爲徵詢這些合同支付的任何佣金。

代理人、經銷商和承銷商可能有權通過我們獲得對抗某些民事責任的賠償，包括《證券法》項下的責任，或者就代理人、經銷商或承銷商可能需要就此作出的支付進行貢獻。代理人、經銷商和承銷商可能會在業務的正常過程中與我們進行交易或提供服務。

我們可能提供的證券，除普通股外，都是沒有建立交易市場的新證券。任何承銷商可能在這些證券中進行市場銷售，但不承擔義務，並可能在任何時候通知而停止任何市場銷售。我們不能保證任何證券的交易市場的流動性。

任何承銷商都可以根據交易所法案下的規定進行超額配售、穩定交易、做空交易和懲罰性報價。超額配售涉及銷售超出發行規模的證券，從而形成一個賣空倉位。這個賣空倉位可能涉及「備兌」賣空或「裸賣」賣空。備兌賣空是指不超過承銷商超額配售選擇權額度的賣空，用於購買相關發行中額外證券。承銷商可以通過行使超額配售選擇權或在公開市場購買證券來平倉任何備兌賣空倉位。爲了判斷他們將如何平倉備兌賣空倉位，承銷商將考慮，除其他事項外，公開市場可購證券的價格與通過超額配售選擇權購買證券的價格相比。裸賣是指超出超額配售選擇權的賣空。承銷商必須通過在公開市場購買證券來平倉任何裸賣倉位。如果承銷商擔心，在定價後的公開市場上，證券價格可能受到下行壓力的影響，可能會更容易產生裸賣倉位，從而可能對購買發行證券的投資者產生不利影響。穩定交易允許出價購買標的證券，旨在確認證券價格，只要穩定買單不超過特定最大金額。懲罰性報價允許承銷商在出售給交易商的證券被購回以平倉做空倉位時，從交易商那裏收回銷售佣金。

Any underwriters who are qualified market makers on The Nasdaq Global Market may engage in passive market making transactions in our common stock, Preferred Stock, and warrants, as applicable on The Nasdaq Global Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded.

Similar to other purchase transactions, an underwriter’s purchase to cover the syndicate short sales or to stabilize the market price of our securities may have the effect of raising or maintaining the market price of our securities or preventing or mitigating a decline in the market price of our securities. As a result, the price of our securities may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of the securities if it discourages resales of the securities.

Neither we nor any underwriter makes any representation or prediction as to the effect that the transactions described above may have on the price of the securities. If such transactions are commenced, they may be discontinued without notice at any time.

The validity of the securities being offered by this prospectus will be passed upon for us by Thompson Hine LLP, New York, New York.

The consolidated financial statements of Conduit Pharmaceuticals Inc. as of and for the years ended December 31, 2023 and 2022, incorporated by reference in this prospectus and registration statement of which this prospectus is a part have been audited by Marcum LLP, an independent registered public accounting firm, as stated in its report thereon, and which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, and are included in reliance upon such report and upon the authority of such firm as experts in accounting and auditing.

This prospectus is part of a shelf registration statement that we have filed with the SEC. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. The SEC maintains an internet website that contains reports, proxy statements, and other information about registrants, like us, that file electronically with the SEC. The address of that website is www.sec.gov. The information contained in, or that can be accessed through, the SEC’s website is not incorporated by reference in, and is not part of, this prospectus or any prospectus supplement.

We are subject to the information and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and other information with the SEC. We maintain a website at http://www.conduitpharma.com. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or any prospectus supplement.

The SEC allows us to “incorporate by reference” information that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus to the extent that a statement contained in this prospectus or free writing prospectus provided to you in connection with this offering, or in any other document we subsequently file with the SEC that also is incorporated by reference in this prospectus, modifies or supersedes the original statement.

The following documents filed with the SEC are hereby incorporated by reference in this prospectus:

All reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to the termination of this offering, including all such reports and other documents filed with the SEC after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to the effectiveness of such registration statement, shall be deemed to be incorporated by reference in this prospectus and to be part hereof from the date of filing of such reports and other documents.

We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You should direct any requests for documents by writing us at 4995 Murphy Canyon Road, Suite 300, San Diego, CA 92134 or by telephoning us at (760) 471-8536.

Notwithstanding the statements in the preceding paragraphs, no document, report, or exhibit (or portion of any of the foregoing) or any other information that we have “furnished” or may in the future “furnish” to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus or any prospectus supplement.

In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.

THE INFORMATION IN THIS PRELIMINARY PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE MAY NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PRELIMINARY PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY JURISDICTION WHERE THE OFFER OR SALE IS NOT PERMITTED.

On October 23, 2024, we entered into a certain Sales Agreement, or sales agreement, with A.G.P./Alliance Global Partners (“A.G.P.”) relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $3,556,586 from time to time through A.G.P., acting as our sales agent or principal.

We are an “emerging growth company” and “smaller reporting company” as defined under U.S. federal securities laws and are subject to reduced public company reporting requirements. Our shares of common stock are listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “CDT”. The last sale price of our shares of common stock on October 16, 2024 was $0.114 per share.

Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). If authorized by us in writing, A.G.P. may also sell shares of our common stock in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or in any other method permitted by law. If we and A.G.P. agree on any method of distribution other than sales of shares of our common stock on or through Nasdaq or another existing trading market in the United States at market prices, we will file a further prospectus supplement providing all information about such offering as required by Rule 424(b) under the Securities Act. A.G.P. is not required to sell any specific number or dollar amount of securities but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between A.G.P. and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The compensation to A.G.P. for sales of common stock sold pursuant to the sales agreement will be equal to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement, in addition to reimbursement of certain expenses. See “Plan of Distribution.” In connection with the sale of the common stock on our behalf, A.G.P. will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of A.G.P. will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to A.G.P. with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

As of October 16, 2024, the aggregate market value of the voting and non-voting common equity held by non-affiliates, computed by reference to the price at which the common equity was last sold on August 26, 2024 of $0.162, was $10,669,758, based on 100,774,035 shares of outstanding common stock as of such date, of which 65,862,708 were held by non-affiliates. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. During the 12 calendar months prior to and including the date of this prospectus supplement, we have sold no securities pursuant to General Instruction I.B.6 of Form S-3.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-4 of this prospectus supplement and the risk factors incorporated by reference into this prospectus supplement and the accompanying prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

本說明書補充和隨附的說明書屬於我們向證券交易委員會（「SEC」）提交的註冊聲明的一部分，利用了「貨架」註冊流程。每次我們根據隨附說明書進行證券銷售之時，我們將提供一個包含有關該發行的具體信息的說明書補充，包括價格、發行的證券數量以及分銷計劃。這種貨架註冊聲明最初是在2024年10月23日向SEC提交的，並於2024年月日被SEC宣佈生效。本說明書補充描述了有關本次發行的具體細節，並可能新增、更新或更改隨附說明書中包含的信息。隨附說明書提供了關於我們及我們的證券的一般信息，其中一些內容，例如名爲「分銷計劃」的部分，可能不適用於本次發行。本說明書補充和隨附的說明書僅是對本次發行的證券提出的要約，但僅限於在法律許可的情況下在特定司法管轄區內進行。我們並不會在任何未經授權的司法管轄區出售或勸誘購買我們的普通股，也不會向任何未經授權或不具備資格的人士進行出售或購買邀約，或向任何在提出邀約或購買邀約爲不合法的人士提供邀約或購買邀約。

如果本招股證書補充資料中的信息與隨附的招股說明書或參照早於此的日期所納入的信息不一致，您應依賴於本招股證書補充資料。本招股證書補充資料連同基礎招股說明書、納入本招股證書補充資料的文件以及隨附的招股說明書和我們授權用於本次發行的任何自由書面招股書包含了與本次發行有關的所有重要信息。我們未授權任何人向您提供不同或額外的信息，您不得依賴於任何未經授權的信息或聲明。您應假定出現在本招股證書補充資料、隨附的招股說明書中、本招股證書補充資料納入的文件中以及隨附的招股說明書中和我們授權用於本次發行的任何自由書面招股書中的信息僅截至那些文件的各自日期爲準。自那些日期以來，我們的業務、財務狀況、經營成果和前景可能已發生變化。在做出投資決定之前，您應該仔細閱讀本招股證書補充資料、隨附的招股說明書以及在此處和其中納入參考的信息和文件，以及我們授權用於本次發行的任何自由書面招股書。請參閱本招股證書補充資料和隨附的招股說明書中的「參照」和「更多信息來源」部分。

本說明書補充僅涉及通過A.G.P.最高售價爲$3,556,586的普通股發行。這些銷售如有，則將根據2024年10月23日我們與A.G.P.簽訂的銷售協議條款進行，該協議副本已被引用到本說明書補充中。

在美國境外沒有采取任何行動以允許這些證券的公開發行或對此說明書補充或與那個司法管轄區相關的配售或分配。在美國境外得到本說明書補充和隨附的說明書的人必須就適用於該司法管轄區的有關此次發行和分銷的限制自我了解並遵守。

本說明書補充和隨附的說明書包含本文所述的某些文件中包含的某些條款和摘要僅爲摘要，不旨在全面。應參考實際文件以獲得完整信息。所有摘要均在其完整的文本中得到限定，其中一些已提交或將提交併在此處引入或隨附。請參見本說明書補充中的「更多信息可在何處查到」。我們進一步指出，我們在任何作爲附件提交到任何文件中的協議中所作的陳述、擔保和金剛交換僅爲該協議的各方（包括某些情況下爲了在這些協議的各方之間分配風險）的利益而作，並不應視爲向您進行的陳述、擔保或金剛交換。此外，這種陳述、保證或金剛交換僅在其所作的日期準確。因此，不應將這種陳述、保證和金剛交換用作準確表示我們事務當前狀態的依據。

本說明書補充和隨附的說明書包含並引用了某些基於公司贊助的研究、獨立行業出版物和其他公開可獲得的信息的市場數據和行業統計數據和預測數據。儘管我們相信這些來源是可靠的，但涉及預測的估計涉及衆多假設，受風險和不確定性影響，並可能因各種因素而發生變化，包括本說明書補充中的「風險因素」和隨附的說明書以及在此處和隨附的文檔中類似的標題。因此，投資者不應過度依賴此信息。

Unless otherwise stated or the context requires otherwise, all references in this prospectus supplement to the “Company,” “we,” “us,” “our”, “CDT” refer to Conduit Pharmaceuticals Inc., a Delaware corporation.

Prospectus Supplement Summary

This summary highlights information contained elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus supplement and the accompanying prospectus carefully, including the section entitled “Risk Factors” beginning on page S-4 and our consolidated financial statements and the related notes and the other information incorporated by reference into this prospectus supplement and the accompanying prospectus, before making an investment decision.

Overview

Conduit has developed a unique business model that allows it to act as a conduit to bring clinical assets from pharmaceutical companies and develop new treatments for patients. Our novel approach addresses unmet medical needs and lengthens the intellectual property for our existing assets through cutting-edge solid-form technology and then commercializing these products with life science companies.

While simultaneously leveraging the capabilities of our Cambridge laboratory facility and highly experienced team of solid-form experts to extend or develop proprietary solid-form intellectual property for our existing and future clinical assets. Our own intellectual property portfolio comprises pending patent applications in several international jurisdictions describing a solid-form compound, the AZD1656 Cocrystal (a HK-4 Glucokinase Activator), targeting a wide range of autoimmune disorders. Our pipeline research includes a number of compounds that serve as promising alternatives to existing clinical assets currently marketed and sold by large pharmaceutical companies, which we have identified as having an opportunity to develop further intellectual property positions through solid-form technology.

In connection with the funding and development of clinical assets, we evaluate and select the specific molecules to be developed and collaborate with external contract research organizations (“CROs”) and Key Opinion Leaders (“KOLs”) to run clinical trials that are managed, funded, and overseen by us. We intend to leverage our comprehensive clinical and scientific expertise in order to facilitate development of clinical assets through Phase II trials in an efficient manner by using CROs and third-party service providers. We will also collaborate closely with disease specific KOLs to collectively assess and determine the most appropriate indications for all our current and forthcoming assets.

We believe that successful Phase II trials of the clinical assets in our pipeline will increase the value of our assets. There is no assurance that any clinical trials on the assets owned or licensed by us will be successful, however, following a successful Phase II clinical trial, we would look to licensing opportunities with large biotech or pharmaceutical companies, typically for up-front milestone payments and royalty income streams for the life of the asset patent. We anticipate using any future royalty income stream to develop our asset portfolio in combination with other potential sources of financing, including debt or equity financing.

除了我們擁有專有專利的臨床資產外，阿斯利康同意根據阿斯利康控制的與Hk-4葡萄糖激酶激活劑AZD1656和AZD5658以及治療、預防和預防特發性男性不育的髓過氧化物酶抑制劑AZD5904相關的知識產權，在所有適應症下向公司授予許可證。公司將負責根據相關許可協議（「許可產品」）開發和商業化相關產品。公司有責任採取商業上合理的努力開發和商業化許可產品。

我們計劃將精力集中在開發臨床資產，以解決影響衆多人口且目前無治療方法或目前治療方法帶來顯著不良副作用的疾病。

我們打算啓動2a期臨床試驗，評估AZD1656用於治療系統性紅斑狼瘡（包括紅斑狼瘡腎炎）和ANCA相關血管炎。這標誌着AZD1656的重大進展，突顯了我們致力於解決未滿足的醫療需求以及對該資產對患者結果產生積極影響的信心。

在系統性紅斑狼瘡患者（包括紅斑狼瘡腎炎患者）和患有ANCA相關血管炎的患者中進行2a期雙盲安慰劑對照試驗，將使我們能夠評估AZD1656在紅斑狼瘡患者的整個範圍內的潛力。同時，我們將評估AZD1656在自身免疫性疾病更廣泛方面的潛力。

企業信息

2023年9月22日，Conduit Pharmaceuticals Limited (「舊Conduit」)、Murphy Canyon Acquisition Corp (「MURF」)和Conduit Merger Sub，Inc.（一家開曼群島豁免公司，MURF的全資子公司）之間的合併交易（「業務組合」）根據合併協議及計劃，於2022年11月8日訂立的，經修訂後，（合併協議）。根據合併協議的條款，在交割時，（i）Merger Sub與Old Conduit合併，Old Conduit作爲MURF的全資子公司生存，（ii）從Murphy Canyon Acquisition Corp改名爲Conduit Pharmaceuticals Inc.

我們的主要執行辦公室位於4995 Murphy Canyon Road, Suite 300, San Diego, California 92123，我們的電話號碼是(760) 471-8536。我們的網站地址是http://www.conduitpharma.com。在我們的網站上包含或可通過其他方式訪問的信息不屬於本招股說明書補充內容。

在此之後將發行的普通股數量是基於2024年10月16日已發行的100,774,035股，不包括：

除非另有說明，本招股說明書補充中的信息不包括期權的行使或權證的行使。

在我們的證券投資涉及高風險。在決定投資我們的證券之前，您應該仔細考慮下面描述的具體風險因素，並在題爲“ 「風險因素」”的部分中討論。 “任何後續季度報告Form 10-Q中的「Item 1A.Risk Factors」條目中的描述，以及出現或可能出現的所有適用招股書中的內容，並在我們向SEC提交的文件中併入引文招股說明書，並在本招股說明書或任何適用的招股書補充（如有）中包含。要了解這些報告和文件的描述和信息以及有關其何處可以找到它們的信息，請參閱「額外信息的獲取方式」。” 內容包括在截至2023年12月31日的財政年度的年度報告Form 10-k中的 “以及在任何隨後的季度報告Form 10-Q中可能描述的內容，均在標題爲” Item 1A. 風險因素中，以及所有適用的招股說明書中的內容，以及包含或將包含在我們向SEC提交併在本招股書補充資料中引用的文件中的內容，連同本招股說明書中包含的所有其他信息，或任何適用的招股說明書。有關這些報告和文件的描述，以及關於這些報告和文件的詳細信息，請參閱「您可以找到更多信息的地方」 和框架。有關詳細信息，請參閱UBS集團報酬報告通過引用包含某些信息.” 如果我們在SEC備案中描述的任何風險或不確定性，或任何招股說明書補充或任何其他風險和不確定性實際發生，我們的業務、財務狀況和經營業績可能會受到重大和不利影響。在這種情況下，我們證券的交易價格可能會下跌，您可能會失去您投資價值的全部或部分。

本次發行的淨收益，我們的管理層將有廣泛的自由裁量權使用，您可能不同意我們使用這些款項的方式，這些款項可能無法投資成功。

我們的管理層將在利用本次發行的淨收益方面擁有廣泛的自由裁量權，而我們的股東將無法在投資決策中評估淨收益的使用情況。由於將影響我們利用本次發行淨收益的因素衆多且變化多端，因此最終使用可能與目前預期的用途大相徑庭。如果我們的管理層未能有效運用這些資金，可能會損害我們的業務。請參閱本發行方案的附錄S-4頁上關於我們擬利用本次發行收益的說明。

我們從未在普通股上支付現金股利，目前也不打算在可預見的未來支付任何現金股利。

購買該交易中的普通股將導致您立即和實質性地稀釋每股賬面價值。

本次發行的股票（如有）將以不同價格不時出售。本次發行的每股發行價格可能超過本次發行之前我公司流通普通股每股的淨有形賬面價值。假設在與A.G.P.簽訂的銷售協議期間銷售了 31,198,123股我公司流通普通股，每股售價爲0.114美元，2024年10月16日，我公司普通股在納斯達克上的最後報價爲每股約360萬美元，您將立即蒙受每股0.05美元的稀釋，代表截至2024年6月30日我公司的摺合淨有形賬面價值每股與假定發行價格之間的差額。在本招股說明書補充之日後未來行使期權以及未行使的期權和2024年6月30日後有關的股票期權行使後，可能會進一步稀釋您的投資。請閱讀下文標題爲「稀釋」的部分，了解如果您參與本次發行將承受的稀釋情況的更詳細說明。

本次發行的普通股票將以「市價」發行，不同時間購買股票的投資者很可能支付不同的價格。

Investors who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid.

The actual number of shares we will issue under the sales agreement with A.G.P., at any one time or in total, is uncertain.

Subject to certain limitations in the sales agreement with A.G.P. and compliance with applicable law, we have the discretion to deliver placement notices to A.G.P. at any time throughout the term of the sales agreement. The number of shares that are sold by A.G.P. after delivering a placement notice will fluctuate based on the market price of the common stock during the sales period and limits we set with A.G.P.

Sales of a significant number of shares of our common stock in the public markets or significant short sales of our common stock, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital.

Sales of a substantial number of shares of our common stock or other equity-related securities in the public markets, could depress the market price of our common stock. This offering may contribute to a depressed market price of our common stock. If there are significant short sales of our common stock, the price decline that could result from this activity may cause the share price to decline more so, which, in turn, may cause long holders of the common stock to sell their shares, thereby contributing to sales of common stock in the market. Such sales also may impair our ability to raise capital through the sale of additional equity securities in the future at a time and price that our management deems acceptable, if at all.

This prospectus supplement and the documents we have filed with the SEC that are incorporated by reference contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to:

In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “intends,” “may,” “plans,” “potential,” “will,” “would,” or the negative of these terms or other similar expressions. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks in the section titled “Risk Factors”, in any prospectus supplement and free writing prospectuses we may authorize for use in connection with this offering, and in our most recent Annual Report on Form 10-K, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus supplement in their entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should read this prospectus supplement, together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements.

We may issue and sell shares of common stock having aggregate sales proceeds of up to $3,556,586 from time to time, before deducting sales agent commissions and expenses. The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under, or fully utilize, the sales agreement with A.G.P.

We intend to use the net proceeds from this offering for working capital and general corporate purposes. This represents our best estimate based on the current status of our business, but we have not reserved or allocated amounts for specific purposes and cannot specify with certainty how or when we will use any of the net proceeds. Additionally, we plan to use the net proceeds to initiate Phase 2a clinical trials evaluating AZD1656 for the treatment of systemic lupus erythematosus, including lupus nephritis, and ANCA-associated vasculitis. These double-blind, placebo-controlled trials will allow us to assess the potential of AZD1656 across the full spectrum of lupus patients and those with ANCA-associated vasculitis, while exploring its broader application in autoimmune disorders. The actual amounts and timing of our expenditures will depend on various factors, and management will have broad discretion in applying the proceeds from this offering.

Pending application of the net proceeds as described above, we intend to invest the proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether the proceeds invested will yield a favorable, or any, return.

We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We expect to retain future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on our common stock will be at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements and any contractual restrictions.

If you invest in our securities in this offering, your ownership interest will be diluted to the extent of the difference between the offering price per share paid by the purchaser in this offering and our pro forma as adjusted net tangible book value per share immediately after this offering.

Our historical net tangible book value as of June 30, 2024 was approximately $(5.8) million, or $(0.08) per share of common stock. We calculate tangible book value (deficit) per share by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of June 30, 2024.

Our pro forma net tangible book value as of June 30, 2024 was approximately $(7.8) million, or $(0.08) per share of common stock. We calculate pro forma net tangible book value per share by dividing (a) the total of (i) our historical net tangible book value, (ii) plus $2.0 million in debt related to the Nirland Promissory note issued on August 7, 2024 by (b) the sum of (i) the total number of shares of our common stock outstanding as of June 30, 2024, and (ii) the number of shares of our common stock issued after June 30, 2024 including 12,500,000 shares issued to Nirland in connection with a promissory note, 9,504,465 issued in connection with the agreement with AstraZeneca and 4,769,336 issued in connection with the extension of the Company’s promissory note and loans payable.

After to giving effect to the offering of $3,556,586 of our common stock at an assumed offering price of $0.114 per share (the closing trading price of our stock on October 16, 2024) and after deducting fees of AGP and estimated offering expenses payable by us, our pro forma as adjusted net tangible book deficit as of June 30, 2024 is $(4.6) million. This represents an immediate decrease in net tangible book deficit of $0.05 per share of common stock, to existing shareholders and an immediate dilution in net tangible book value of $0.16 per share of common stock, to purchasers of common stock in this offering at an assumed offering price of $0.114.

The foregoing discussion and table illustrates the dilution in net tangible book value per share to new investors as of June 30, 2024. The foregoing table illustrates this calculation on a per share basis. The pro forma as adjusted information is illustrative only and will adjust based on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time shares of our common stock are sold pursuant to this prospectus supplement. The shares sold in this offering, if any, will be sold from time to time at various prices. We will not offer and sell shares in excess of any amount that would cause the number of our outstanding shares to exceed the number of shares then authorized to be issued under our certificate of incorporation.

The discussion and table above assume no exercise of outstanding options or warrants. To the extent that options or warrants are exercised, you may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

We have entered into the sales agreement with A.G.P. under which we may issue and sell shares of our common stock from time to time up to $3,556,586 million to or through A.G.P., acting as our sales agent or principal. The sales of our common stock, if any, under this prospectus supplement will be made at market prices by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on Nasdaq, on any other existing trading market for our common stock or to or through a market maker. If we and A.G.P. agree on any method of distribution other than sales of shares of our common stock on or through Nasdaq or another existing trading market in the United States at market prices, we will file a further prospectus supplement providing all information about such offering as required by Rule 424(b) under the Securities Act.

Each time that we wish to issue and sell shares of our common stock under the sales agreement, we will provide A.G.P. with a placement notice describing the amount of shares to be sold, the time period during which sales are requested to be made, any limitation on the amount of shares of common stock that may be sold in any single day, any minimum price below which sales may not be made or any minimum price requested for sales in a given time period and any other instructions relevant to such requested sales. Upon receipt of a placement notice, A.G.P., acting as our sales agent, will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of Nasdaq, to sell shares of our common stock under the terms and subject to the conditions of the placement notice and the sales agreement. We or A.G.P. may suspend the offering of common stock pursuant to a placement notice upon notice and subject to other conditions.

Settlement for sales of common stock, unless the parties agree otherwise, will occur on the first trading day following the date on which any sales are made in return for payment of the net proceeds to us. There are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and A.G.P. may agree upon.

Because there are no minimum sale requirements as a condition to this offering, the actual total public offering price, commissions and net proceeds to us, if any, are not determinable at this time. The actual dollar amount and number of shares of common stock we sell through this prospectus supplement will be dependent, among other things, on market conditions and our capital raising requirements.

We will report at least quarterly the number of shares of common stock sold through A.G.P. under the sales agreement, the net proceeds to us and the compensation paid by us to A.G.P. in connection with the sales of common stock under the sales agreement.

The offering pursuant to the sales agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the sales agreement and (ii) termination of the sales agreement as permitted therein. We may terminate the sales agreement in our sole discretion at any time by giving five days’ prior notice to A.G.P. A.G.P. may terminate the sales agreement under the circumstances specified in the sales agreement and in its sole discretion at any time by giving five days’ prior notice to us.

This prospectus supplement in electronic format may be made available on a website maintained by A.G.P., and A.G.P. may distribute this prospectus supplement electronically.

We will pay A.G.P. commissions for its services in acting as our sales agent in the sale of our common stock pursuant to the sales agreement. A.G.P. will be entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of our common stock on our behalf pursuant to the sales agreement. We have also agreed to reimburse A.G.P. for its reasonable and documented out-of-pocket expenses (including but not limited to the reasonable and documented fees and expenses of its legal counsel) in an amount not to exceed $50,000 and up to an additional $20,000 per fiscal year for maintenance.

We estimate that the total expenses for this offering, excluding compensation payable to A.G.P. and certain expenses reimbursable to A.G.P. under the terms of the sales agreement, will be approximately $140,000. The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock.

In connection with the sale of the common stock on our behalf, A.G.P. will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of A.G.P. will be deemed to be underwriting commissions or discounts.

A.G.P. will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus supplement if such activity would be prohibited under Regulation M or other anti-manipulation rules under the Securities Act. As our sales agent, A.G.P. will not engage in any transactions that stabilizes our common stock.

We have agreed to indemnify A.G.P. against certain civil liabilities, including liabilities under the Securities Act and the Exchange Act, and to contribute to payments that the A.G.P. may be required to make in respect of such liabilities.

A.G.P. and/or its affiliates have in the past engaged, and may in the future engage, in transactions with, and may perform, from time to time, investment banking and advisory services for us in the ordinary course of their business and for which it would receive customary fees and expenses. In addition, in the ordinary course of its business activities, A.G.P. and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for its own account and for the accounts of its customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates.

A.G.P. was a financial advisor to both the Company and Old Conduit in connection with the Business Combination transaction. Upon the completion of the Business Combination, A.G.P.: (i) received a cash fee of $6,500,000, 1,300,000 shares of our common stock, and warrants to purchase 54,000 shares of common stock at an exercise price of $11.00 per share pursuant to its engagement agreement with Old Conduit entered into on August 2, 2022, and (ii) agreed to defer payment, to be paid in the future under certain circumstances by a date no later than March 21, 2025, of $5,737,500 of fees as a result of its engagement for the initial public offering.

The validity of the common stock offered hereby will be passed upon for us by Thompson Hine LLP, New York, New York. Sullivan & Worcester LLP, New York, New York, is acting as counsel for the sales agent in connection with this offering.

The consolidated financial statements of Conduit Pharmaceuticals Inc. as of and for the years ended December 31, 2023 and 2022, incorporated by reference in this prospectus and registration statement of which this prospectus is a part have been audited by Marcum LLP, an independent registered public accounting firm, as stated in its report thereon, included therein and which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, and are included in reliance upon such report and upon the authority of such firm as experts in accounting and auditing.

The SEC allows us to “incorporate by reference” information that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus supplement. Information in this prospectus supplement supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement, while information that we file later with the SEC will automatically update and supersede the information in this prospectus supplement to the extent that a statement contained in this prospectus or free writing prospectus provided to you in connection with this offering, or in any other document we subsequently file with the SEC that also is incorporated by reference in this prospectus supplement, modifies or supersedes the original statement.

The following documents filed with the SEC are hereby incorporated by reference in this prospectus supplement:

●

the description of our securities contained in our Annual Report on Form 10-K, filed with the SEC on April 16, 2024, as well as any additional amendments or reports filed for the purpose of updating such description.

All reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination of this offering, including all such reports and other documents filed with the SEC after the date of the initial filing of the registration statement of which this prospectus supplement forms a part and prior to the effectiveness of such registration statement, shall be deemed to be incorporated by reference in this prospectus supplement and to be part hereof from the date of filing of such reports and other documents.

This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 we filed with the SEC under the Securities Act and do not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus supplement or the accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy information filed by us with the SEC at the SEC’s public reference section, 100 F Street, N.E., Washington, D.C. 20549. Information regarding the operation of the public reference section can be obtained by calling 1-800-SEC-0330. The SEC also maintains an Internet site at http://www.sec.gov that contains reports, statements and other information about issuers, such as us, who file electronically with the SEC.

We also maintain a website at www.conduitpharma.com through which you can access our SEC filings free of charge. The information set forth on our website is not part of this prospectus supplement.

The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the offering of the securities pursuant to this registration statement:

Section 145 of the DGCL concerning indemnification of officers, directors, employees and agents is set forth below.

“Section 145. Indemnification of officers, directors, employees and agents; insurance.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

Section 8.2 of the Company’s second amended and restated certificate of incorporation provides:

“(a) To the fullest extent permitted by applicable law, as the same exists or may hereafter be amended, the Corporation shall indemnify and hold harmless each person who is or was made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “proceeding”) by reason of the fact that he or she is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan (an “indemnitee”), whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys’ fees, judgments, fines, ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred by such indemnitee in connection with such proceeding. The Corporation shall to the fullest extent not prohibited by applicable law pay the expenses (including attorneys’ fees) incurred by an indemnitee in defending or otherwise participating in any proceeding in advance of its final disposition; provided, however, that, to the extent required by applicable law, such payment of expenses in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking, by or on behalf of the indemnitee, to repay all amounts so advanced if it shall ultimately be determined that the indemnitee is not entitled to be indemnified under this Section 8.2 or otherwise. The rights to indemnification and advancement of expenses conferred by this Section 8.2 shall be contract rights and such rights shall continue as to an indemnitee who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators. Notwithstanding the foregoing provisions of this Section 8.2(a), except for proceedings to enforce rights to indemnification and advancement of expenses, the Corporation shall indemnify and advance expenses to an indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board.

(b) The rights to indemnification and advancement of expenses conferred on any indemnitee by this Section 8.2 shall not be exclusive of any other rights that any indemnitee may have or hereafter acquire under law, this Second Amended and Restated Certificate, the ByLaws, an agreement, vote of stockholders or disinterested directors, or otherwise.

(c) Any repeal or amendment of this Section 8.2 by the stockholders of the Corporation or by changes in law, or the adoption of any other provision of this Second Amended and Restated Certificate inconsistent with this Section 8.2, shall, unless otherwise required by law, be prospective only (except to the extent such amendment or change in law permits the Corporation to provide broader indemnification rights on a retroactive basis than permitted prior thereto), and shall not in any way diminish or adversely affect any right or protection existing at the time of such repeal or amendment or adoption of such inconsistent provision in respect of any proceeding (regardless of when such proceeding is first threatened, commenced or completed) arising out of, or related to, any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision.

(d) This Section 8.2 shall not limit the right of the Corporation, to the extent and in the manner authorized or permitted by law, to indemnify and to advance expenses to persons other than indemnitees.”

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable.

See the Exhibit Index on the page immediately following the signature page to this registration statement for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

Provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the Registration Statement as of the date the filed prospectus was deemed part of and included in the Registration Statement; and

(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a Registration Statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the Registration Statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the Registration Statement relating to the securities in the Registration Statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a Registration Statement or prospectus that is part of the Registration Statement or made in a document incorporated or deemed incorporated by reference into the Registration Statement or prospectus that is part of the Registration Statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the Registration Statement or prospectus that was part of the Registration Statement or made in any such document immediately prior to such effective date;

(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(1) the information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act of 1933 shall be deemed to be a part of the registration statement as of the time it was declared effective; and

(2) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(d) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

(e) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of section 310 of the Trust Indenture Act (“Act”) in accordance with the rules and regulations prescribed by the Commission under section 305(b)(2) of the Act.

* To be filed by amendment or incorporated by reference in connection with the offering of the securities.

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of San Diego, State of California, on October 23, 2024.

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David Tapolczay and/or James Bligh, as his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.



關於本說明書補充	S-1
概要	S-2
本次發行	S-4
風險因素	S-4
關於前瞻性聲明的特別說明	S-6
使用收益	S-7
股息政策	S-7
稀釋	S-7
分銷計劃	S-9
法律事項	S-11
專家	S-11
參考相關信息的合併	S-11
您可以在哪裏找到額外信息	S-12

普通股份提供		根據銷售協議，我們的普通股股票總髮行價高達$3,556,586。

發行方式		「按市價發行」可能會不時通過A.G.P.作爲銷售代理或委託人進行。請參閱「分銷計劃」。

目前的普通股份		100,774,035

本次發行後立即成爲流通股的普通股		假設以每股$0.114的價格銷售，我們的普通股股票最多可達131,972,158股，這是2024年10月16日納斯達克收盤價。根據本次發行不時出售股票的價格，實際發行股數將有所不同。

所得款項的用途		我們打算將本次發行的淨收益用於營運資金和一般企業用途。請參閱招股說明書S-7頁上的「使用收益」部分，以獲取對本次發行的預期收益用途的更完整描述。

風險因素。		投資我們的證券涉及高度風險。請查看本招股說明書S-4頁開頭的「風險因素」部分以及本招股說明書和附屬招股說明書中所引用的風險因素。

納斯達克全球貨幣市場標的		CDt。

	●	17,740,725 普通股票下的每股普通股股份認股權證以10.68美元的加權平均行權價

	●	1,006,719 普通股下的普通股份期權，每股5.51美元的加權平均行權價

		80,000 可轉換債券到期日爲2024年11月19日，對應我們普通股中的任何或所有部分股份

	●	14,107,834 可供未來發行的股份，根據 Conduit Pharmaceuticals Inc. 2023股權激勵計劃。

Assumed offering price per share	$	0.114
Historical net tangible book deficit per share as of June 30, 2024		(0.08	)
Pro forma increase in net tangible book value per share		0.00
Pro forma net tangible book value per share as of June 30, 2024		(0.08	)
Decrease per share attributable to investors in this offering		0.05
Pro forma as adjusted net tangible book value per share after this offering		(0.03	)
Dilution per share to investors in this offering	$	0.15

SEC registration fee	$	15,310
Accounting fees and expenses	$	*
Legal fees and expenses	$	*
Printing and miscellaneous expenses	$	*
Total	$	*

大型加速文件提交人	☐	加速文件提交人	☐
非加速文件提交人	☒	小型報告公司	☒
		新興成長公司	☒

關於本招股說明書		1
簡式招股書概要		2
風險因素		3
我們可能發行的證券		10
有關前瞻性陳述的特別提示		11
募集資金的用途		12
普通股的描述		13
優先股的描述		14
認股權證描述		15
份額描述		17
公司章程和公司規則的防止收購效應		18
證券的合法所有權		19
配售計劃		23
法律問題		25
專家		25
您可以在哪裡找到更多的資訊？		25
透過引用納入特定資訊		25

●	能夠以可接受的條件或根本無法籌集額外資金，用於支持我們當前的臨床前和臨床計劃；

●	我們的臨床試驗是否能夠及時完成，可能明顯比我們目前預期的要慢或成本更高，主要取決於第三方承包商的表現；

●	我們是否需要根據FDA或類似的外國監管機構的要求，開展額外的臨床前或臨床試驗，超出計劃以支持我們的臨床資產或任何未來的臨床資產的批准和商業化；

●	FDA或類似的外國監管機構是否接受我們提出的適應症及與我們臨床資產提出的適應症相關的主要終點評估；

●	我們能夠證明我們臨床資產或任何未來臨床資產的安全性和有效性，以滿足FDA和類似的外國監管機構的要求;

●	在與我們的臨床資產或未來獲批產品可能發生的潛在副作用的患者中，副作用的普遍程度、持續時間和嚴重程度;

●	及時獲得FDA和類似的外國監管機構的必要營銷批准;

●	實現和維持，並在適用的情況下，確保我們的第三方承包商實現並維持，符合我們的合同義務和適用於我們的臨床資產或任何未來臨床資產或獲批產品的所有監管要求;

●	我們與第三方簽訂的製造我們臨床資產或任何未來臨床資產的臨床試驗和商業供應的能力，保持與監管機構良好關係，並開發、驗證和保持符合當前良好製造規範（「cGMP」）的商業化製造流程；

●	在臨床資產或任何未來臨床資產獲批准之前和之後繼續保持接受安全性資料。

●	我們在美國和國際上成功商業化我們目前的臨床資產或將來的任何臨床資產的能力，如果在這些國家和地區獲得批准後進行市場營銷、銷售和分銷，無論是獨立進行還是與他人合作；

●	醫生、患者和付款方對我們目前的臨床資產或將來的任何臨床資產的益處、安全性和療效是否獲得認可，包括相對於替代和競爭性治療的情況；

●	我們能否遵守衆多後批准監管要求；

●	我們及我們合作伙伴在我們目前的臨床資產或將來的任何臨床資產的知識產權方面建立和強制執行能力；

●	我們及合作伙伴避免第三方專利干涉或知識產權侵權索賠的能力；和

●	我們可以成功地收購或取得額外的臨床資產或已上市產品，並相信我們可以成功開發和推廣。

●	我們在職責分離方面存在一定的侷限性。在審計期間，Old Conduit並沒有在財務會計和報告部門配備內部人員，而是依賴第三方顧問執行這些活動。

●	我們缺乏對財務報表的審核和批准的正式流程。在審計期間，尤其是在業務組合之前，財務報表中出現了許多重複的錯誤，涉及帳戶餘額和披露，這導致了有合理可能性未能及時發現重大錯誤。

●	我們沒有設計出符合適當的內部控制框架的充足和適當的內部控制，包括監控控制和某些實體級別的控制。

●	我們沒有適當審查和評估審計期間發生的所有重大交易的會計影響，這導致了對之前期間的重新報表。

●	我們臨床試驗的進展、時間、範圍和成本，包括及時招募潛在未來臨床試驗的患者能力;

●	FDA和類似監管機構的審批結果、時間和成本，包括FDA或類似監管機構可能要求我們進行更多研究的潛在可能性超出我們當前的預期;

●	來自我們當前臨床資產或任何未來臨床資產的收入金額（如果有）;

●	我方可能建立以下潛在未來合作、許可或其他安排的條件和時間;

●	未來收購和/或其他臨床資產開發的現金需求；

●	作爲一家上市公司運營的成本；

●	回應技術和市場發展所需的時間和成本；

●	我們、員工、合作伙伴或其他潛在業務夥伴之間可能發生的任何糾紛；及

●	起草、申請、辯護和執行任何專利索賠和其他知識產權的成本。

●	我們有能力滿足未來的資本需求，用於資助我們的業務，可能涉及債務和/或股權融資，並且能夠以優惠條款獲得此類債務和/或股權融資，以及我們的現金來源和使用情況

●	我們有能力維持證券在納斯達克的上市地位，以及證券的流動性和交易

●	發生任何事件、變化或其他情況，包括可能針對我們提起的任何法律訴訟的結果

●	我們當前計劃和業務受到干擾的風險

●	我們業務和業務組合（如上所定義）預期收益的識別能力，可能受到競爭等其他因素的影響，包括增長能力、盈利能力的管理以及保留關鍵員工的能力；

●	與我們業務相關的成本；

●	適用法律或法規的變更；

●	我們開展計劃以開發和商業化我們當前的臨床資產，以及我們可能許可的任何未來臨床資產的能力，以及任何此類商業化的時間安排；

●	我們能夠維持現有的許可協議能力;

●	我們對支出、未來營業收入、資本需求和額外融資需求的估計;

●	我們未來能夠實現並保持盈利能力;

●	我們的財務表現；和

●	其他在「」段落下披露的因素風險因素本文所述。

	●	our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 16, 2024;

	●	our Quarterly Reports on Form 10-Q for the period ended March 31, 2024 and June 30, 2024, filed with the SEC on May 14, 2024 and August 12, 2024, respectively;

	●	our Current Reports on Form 8-K, filed with the SEC on April 16, 2024, May 31, 2024, July 1, 2024, July 11, 2024, August 7, 2024, August 8, 2024, August 16, 2024, September 6, 2024, and October 15, 2024; and

	●	our ability to meet future capital requirements to fund our operations, which may involve debt and/or equity financing, and to obtain such debt and/or equity financing on favorable terms, and our sources and uses of cash

	●	the ability to maintain the listing of our securities on Nasdaq, and the potential liquidity and trading of our securities;

	●	the occurrence of any event, change or other circumstances, including the outcome of any legal proceedings that may be instituted against us;

	●	the risk of disruption to our current plans and operations;

	●	the ability to recognize the anticipated benefits of our business and the Business Combination (as defined above), which may be affected by, among other things, competition and the ability to grow, manage growth profitably, and retain key employees;

	●	costs related to our business;

	●	changes in applicable laws or regulations;

	●	our ability to execute our plans to develop and commercialize our current clinical assets, as well as any future clinical assets that we license, and the timing of any such commercialization;

	●	our ability to maintain existing license agreements;

	●	our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;

	●	our ability to achieve and maintain profitability in the future;

	●	our financial performance; and

	●	other factors disclosed under the section entitled “Risk Factors” herein.

	●	17,740,725 shares of common stock underlying outstanding warrants at a weighted average exercise price of $10.68 per share;

	●	1,006,719 shares of common stock underlying outstanding option at a weighted average exercise price of $5.51 per share;

	●	80,000 shares of our common stock issuable upon conversion of any or all of our $0.8 million in outstanding convertible notes due November 19, 2024; and

	●	14,107,834 shares available for future issuance under the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan.

(a)	A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person’s conduct was unlawful.

(b)	A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

(d)	除非由法院命令，否則根據本條款(a)和(b)項的規定，公司只有在認定在此情況下對現任或前任董事、高級職員、僱員或代理適用，並且此人已滿足本條款(a)和(b)項所規定的行爲準則的情況下授權進行補償。對於在作出此決定時是公司的董事或高級職員的人員，應根據以下的決定方式進行：(1)通過不參與此訴訟、訴訟或程序的多數董事投票，即使不足法定人數；或者(2)通過由多數董事指定的委員會的投票，即使不足法定人數；或者(3)如果沒有此類董事，或者如果此類董事這樣指示的話，通過獨立法律顧問的書面意見；或者(4)通過股東的決定。

(e)	公司可以在最終解決此訴訟、訴訟或程序之前，根據此條款的規定，事先支付發生於董事或高級職員在辯護任何民事、刑事、行政或調查性訴訟、訴訟或程序時的費用（包括律師費），條件是該董事或高級職員或他人代表該董事或高級職員承諾，如果最終確定該人沒有資格獲得公司根據本條款的授權提供補償，其將償還該金額。對於前任董事和高級職員或公司的其他僱員和代理，以及在公司的請求下擔任另一家公司、合夥企業、合資企業、信託或其他企業的董事、高級職員、僱員或代理的人員，在公司認爲適當的情況下可以支付此類費用（包括律師費）以及相關條款和條件。

(f)	根據本條款其他的項所提供或授予的補償和費用預先支付不得被視爲涵蓋請求獲得根據任何章程、協議、股東投票或持無利益的董事所授與的任何其他權利的專有權，無論是關於此人在其公務職責中採取的行動，還是在擔任此職務期間採取的其他行動。關於根據公司章程或公司規程的條款而產生的補償或費用預先支付的權利，在有關此補償或費用預先支付的民事、刑事、行政或調查性訴訟、訴訟或程序受理之前進行的公司章程或公司規程的修正、廢止或撤銷將不會消除或削弱該權利，除非發生了構成此訴訟、訴訟或程序的行爲或省略的行爲之後的情況，而該條款在此行爲或省略發生後明確授權此類消除或削弱。

	For purposes of paragraph (g)(1) of this section, the conduct of an insured person shall not be imputed to any other insured person. A corporation that establishes or maintains a captive insurance company that provides insurance pursuant to this section shall not, solely by virtue thereof, be subject to the provisions of Title 18.

(h)	For purposes of this section, references to “the corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under this section with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued.

(i)	For purposes of this section, references to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to “serving at the request of the corporation” shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the corporation” as referred to in this section.

(j)	The indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

(k)	The Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification brought under this section or under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The Court of Chancery may summarily determine a corporation’s obligation to advance expenses (including attorneys’ fees).

Exhibit Number		Description of Document
1.1*		Form of Underwriting Agreement
2.1		Agreement and Plan of Merger Agreement dated as of November 8, 2022, by and among Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc. and Conduit Pharmaceuticals Limited (filed as Annex A-1 to the Registration’s Proxy Statement/Prospectus filed on August 11, 2023, and incorporated herein by reference)
2.2		Amendment to Agreement and Plan of Merger dated as of January 27, 2023, by and among Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc. and Conduit Pharmaceuticals Limited (filed as Annex A-2 to the Registrant’s Proxy Statement/Prospectus filed on August 11, 2023, and incorporated herein by reference).
2.3		Second Amendment to Agreement and Plan of Merger dated as of May 11, 2023, by and among Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc. and Conduit Pharmaceuticals Limited (filed as Annex A-3 to the Registrant’s Proxy Statement/Prospectus filed on August 11, 2023, and incorporated herein by reference).
4.1		Specimen Common Stock Certificate of Conduit Pharmaceuticals Inc. (filed as Exhibit 4.8 to the Registrant’s Amendment No. 3 to Registration Statement on Form S-4 (File No. 333-271903) filed on August 8, 2023, and incorporated herein by reference).
4.2		Specimen Warrant Certificate of Conduit Pharmaceuticals Inc. (filed as Exhibit 4.9 to the Registrant’s Amendment No. 3 to Registration Statement on Form S-4 (File No. 333-271903) filed on August 8, 2023 and incorporated herein by reference.
4.3*		Form of Certificate of Designation
4.4*		Form of Preferred Stock Certificate
4.5*		Form of Warrant Agreement
4.6*		Form of Unit Certificate
5.1		Opinion of Thompson Hine LLP
10.1		Sales Agreement dated October 23, 2024 between Conduit Pharmaceuticals Inc. and A.G.P / Alliance Global Partners
23.1		Consent of Thompson Hine LLP (included in Exhibit 5.1)
23.2		Consent of Marcum LLP, Independent Registered Public Accounting Firm
24.1		Power of Attorney (included on signature page)
107		Filing Fee Table

CONDUIT PHARMACEUTICALS INC.

By:	/s/ David Tapolczay
Name:	David Tapolczay
Title:	Chief Executive Officer

Signature	Title	Date

/s/ David Tapolczay	Chief Executive Officer and Director	October 23, 2024
David Tapolczay	(Principal Executive Officer)

/s/ James Bligh	Interim Chief Financial Officer and Director	October 23, 2024
James Bligh	(Principal Financial Officer and Principal Accounting Officer)

/s/ Freda Lewis-Hall	Director and Chairperson of the Board of Directors	October 23, 2024
Freda Lewis-Hall

/s/ Faith L. Charles	Director	October 23, 2024
Faith L. Charles

	Director	October 23, 2024
Chele Chiavacci Farley

/s/ Andrew Regan	Director	October 23, 2024
Andrew Regan